Joint CMO/TGA statement - Concerns regarding the public health risks associated with unapproved peptide products
16th July 2026
The TGA and Australia’s Chief Medical Officer published a joint statement on 19 June 2026 regarding the public health risks associated with unapproved peptide products such as retatrutide.
The statement outlines actions to take if you suspect an adverse event or non-compliance in relation to therapeutic goods, which includes the supply of an unapproved therapeutic product.
In addition to these actions, if you suspect unauthorised prescribing, possession or supply of medicines in the ACT, please notify the Health Protection Service on (02) 5124 9700 or via email at hps@act.gov.au.